Please login to the form below

Not currently logged in
Email:
Password:

Ixempra

This page shows the latest Ixempra news and features for those working in and with pharma, biotech and healthcare.

Bayer fails to overturn Nexavar compulsory licence in India

Bayer fails to overturn Nexavar compulsory licence in India

There have already been suggestions that Roche's breast cancer treatment Herceptin (trastuzumab) and Bristol-Myers Squibb's leukaemia medicine Sprycel (dasatinib) and chemotherapy Ixempra (ixabepilone) could follow Nexavar down this

Latest news

  • India could hit Roche and BMS with compulsory licences India could hit Roche and BMS with compulsory licences

    India could hit Roche and BMS with compulsory licences. Generic versions of Herceptin, Sprycel and Ixempra may reach market before patent expiration. ... According to the Indian Express, Herceptin, Ixempra and Sprycel cost 50, 000 rupees (687), 70, 000-80

  • Paclitaxel tops newer drugs in comparative breast cancer study

    Paclitaxel tops newer drugs in comparative breast cancer study. Surprise result shows it bests Celgene's Abraxane and BMS' Ixempra. ... nab] paclitaxel) and 7.6 months with Bristol-Myers Squibb's Ixempra (ixabepilone) in the cohort of chemotherapy-naïve

  • Eisai wins approval for breast cancer drug

    and with Bristol-Myers Squibb's Ixempra (ixabepilone), which is marketed for patients with late- stage disease after failure of an anthracycline, taxane and Xeloda.

  • Bristol-Myers signs cancer drug deal

    BMS' existing cancer-drug portfolio includes Erbitux (cetuximab), Ixempra (ixabepilone) and Sprycel (dasatinib).

  • FDA approves BMS chemotherapy drug

    Ixempra was approved for use in women who have failed treatment on three other types of chemotherapy. ... Ixempra inhibits the protein tubulin, which stops cells growing and dividing by arresting the cell cycle.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics